The discovery of blood-circulating biomarkers is hindered by the large dynamic range of blood components and the low concentration of disease-specific molecules. We employ the Nanoomics platform in order to facilitate the discovery of novel biomarker panels in blood (using both preclinical models and human clinical samples), for a range of diseases and biomarker applications with an emphasis on the early detection of cancer and neurodegenerative diseases.  We aim to develop nanoparticle-based ‘liquid biopsy’ platforms to harvest disease-specific molecules across multiple omics ‘layers’.